Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Argenx's Subcutaneous Efgartigimod At Par With Intravenous Administration In Neuromuscular Disorder

Argenx SE (NASDAQ:ARGX) ) has announced topline data from the Phase 3 ADAPT-SC study evaluating subcutaneous (SC) efgartigimod for generalized myasthenia gravis (gMG). 

  • Myasthenia gravis is a chronic autoimmune neuromuscular disease that causes weakness in the skeletal muscles.
  • SC efgartigimod achieved the primary endpoint of total IgG reduction from baseline at day 29, demonstrating statistical noninferiority to Vyvgart (efgartigimod alfa-fcab) intravenous (IV) formulation. 
  • Argenx plans to submit a Biologics License Application (BLA) to the FDA by the end of 2022.
  • SC efgartigimod is co-formulated with recombinant human hyaluronidase PH20 (rHuPH20), Halozyme Therapeutics Inc's (NASDAQ:HALO) ENHANZE drug delivery technology that facilitates subcutaneous injection delivery of biologics that are typically administered via infusion.
  • Related: Argenx's Vyvgart Wins FDA Approval For Autoimmune, Neuromuscular Disease.
  • SC efgartigimod demonstrated a mean total IgG reduction of 66.4% from baseline at day 29, compared to 62.2% with Vyvgart. 
  • Additional key secondary endpoints were met, consistent with clinical efficacy results seen in the Vyvgart Phase 3 ADAPT study, 
  • SC efgartigimod demonstrated a safety profile consistent with the Phase 3 ADAPT study. It was generally well-tolerated.
  • Price Action: ARGX shares are up 3.92% at $310.21 during the market session on the last check Tuesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.